SURGERY FOLLOWED BY CHEMORADIOTHERAPY + C225 FOR HEAD AND NECK CARCINOMA

手术后进行放化疗 C225 治疗头颈癌

• 批准号: 7375536
• 负责人: PAUL M HARARI
• 金额: $ 0.43万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375536
• 关键词: SURGERY; FOLLOWED; CHEMORADIOTHERAPY; C225; HEAD

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (from ClinicalTrials.gov) RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Cisplatin and docetaxel may make the tumor cells more sensitive to radiation therapy. Combining a monoclonal antibody with chemoradiotherapy and giving them after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase II trial is studying adjuvant cetuximab given together with chemoradiotherapy using cisplatin to see how well it works compared to adjuvant cetuximab given together with chemoradiotherapy using docetaxel in treating patients with resected stage III or stage IV squamous cell carcinoma (cancer) or lymphoepithelioma of the head and neck.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。 （摘自Clinicaltrials.gov）基本原理：单克隆抗体（例如西妥昔单抗）可以定位肿瘤细胞，杀死它们或向其杀死肿瘤的物质而不会损害正常细胞。化学疗法中使用的药物（例如顺铂和多西他赛）以不同的方式起作用，以阻止肿瘤细胞分裂，从而停止生长或死亡。放射疗法使用高能X射线来损害肿瘤细胞。顺铂和多西他赛可能会使肿瘤细胞对放射治疗更敏感。将单克隆抗体与化学疗法相结合并在手术后给予它们，可能会杀死任何剩余的肿瘤细胞。 目的：这项II期随机试验是研究辅助西素单抗与化学疗法使用顺铂一起进行的，以查看与辅助性西妥昔单抗与化学放疗辅助疗法相比，使用多西他赛在治疗切除的III期或IV期IV期鳞状细胞癌（癌症）或Lymphoepepepeepepetheelimama和newselliymamoma和newselliephectithelimomamoma和newselliymomamoma和newselliyphectitheliamoma and and the thealliemomamoma上和NewseLiamoma和newseLiamoma show and the Heald和newseLiamoma。